MONTREAL, May 14 /CNW Telbec/ - Akela Pharma Inc. (TSX: "AKL"), a drug
development company focused on developing therapies for the inhalation and
pain markets, today announced that it has won the "Best Abstract Reward" at
the recent 11th Asia Pacific Congress of Nephrology in Kuala Lumpur in the
"International Abstract" category for its GHRH Phase II results abstract.
